Variations in testosterone pathway genes and susceptibility to testicular cancer in Norwegian men

International Journal of Andrology

Volumn 35, Issue 6, 2012, Pages 819-827

  Kristiansen, W ^a   Aschim, E L ^a   Andersen, J M ^a   Witczak, O ^a   Fossa S D ^b,c   Haugen, T B ^a  

^a OSLO METROPOLITAN UNIVERSITY   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

5 reductase II; Androgen receptor; Luteinizing hormone receptor; Polymorphisms; Steroid hormone metabolism; Testicular cancer

Indexed keywords

ANDROGEN RECEPTOR; LUTEINIZING HORMONE RECEPTOR; STEROID 5ALPHA REDUCTASE 2; TESTOSTERONE;

ADULT; ALLELE; ARTICLE; CANCER SUSCEPTIBILITY; EXON; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SEMINOMATOUS GERMINOMA; NORWAY; PRIORITY JOURNAL; SEMINOMA; SINGLE NUCLEOTIDE POLYMORPHISM; TESTIS CANCER;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MEMBRANE PROTEINS; MUTATION; NORWAY; POLYMORPHISM, GENETIC; RECEPTORS, ANDROGEN; RECEPTORS, LH; TESTICULAR NEOPLASMS; TESTOSTERONE;

EID: 84869874606     PISSN: 01056263     EISSN: 13652605     Source Type: Journal    
DOI: 10.1111/j.1365-2605.2012.01297.x     Document Type: Article

References (48)

1. Altman DG. (1991) Practical Statistics for Medical Research. Chapman and Hall, London, p. 611.
2. Brooks BP & Fischbeck KH. (1995) Spinal and bulbar muscular atrophy: a trinucleotide-repeat expansion neurodegenerative disease. Trends Neurosci 18, 459-461.
3. Chia VM, Quraishi SM, Devesa SS, Purdue MP, Cook MB & McGlynn KA. (2010) International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev 19, 1151-1159.
4. Dieckmann KP & Pichlmeier U. (2004) Clinical epidemiology of testicular germ cell tumors. World J Urol 22, 2-14.
5. Dong C, Lönnstedt I & Hemminki K. (2001) Familial testicular cancer and second primary cancers in testicular cancer patients by histological type. Eur J Cancer 37, 1878-1885.
6. Fossa SD, Dahl AA & Loge JH. (2003) Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol 21, 1249-1254.
7. Garolla A. (2005) Molecular analysis of the androgen receptor gene in testicular cancer. Endocr Relat Cancer 12, 645-655.
8. Giwercman A, Lundin KB, Eberhard J, Stahl O, Cwikiel M, Cavallin-Stahl E & Giwercman YL. (2004) Linkage between androgen receptor gene CAG trinucleotide repeat length and testicular germ cell cancer histological type and clinical stage. Eur J Cancer 40, 2152-2158.
9. Heimdal K, Olsson H, Tretli S, Flodgren P, Borresen AL & Fossa SD. (1996) Familial testicular cancer in Norway and southern Sweden. Br J Cancer 73, 964-969.
10. Hemminki K & Li X. (2004) Familial risk in testicular cancer as a clue to a heritable and environmental aetiology. Br J Cancer 90, 1765-1770.
11. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G & Skakkebaek NE. (2005) Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 16, 863-868.
12. Holl K, Lundin E, Surcel H-M, Grankvist K, Koskela P, Dillner J et al. (2009) Endogenous steroid hormone levels in early pregnancy and risk of testicular cancer in the offspring: a nested case-referent study. Int J Cancer 124, 2923-2928.
13. Huyghe E, Matsuda T & Thonneau P. (2003) Increasing incidence of testicular cancer worldwide: a review. J Urol 170, 5-11.
14. Jacobsen R, Moller H, Thoresen SO, Pukkala E, Kjaer SK & Johansen C. (2006) Trends in testicular cancer incidence in the Nordic countries, focusing on the recent decrease in Denmark. Int J Androl 29, 199-204.
15. Kanetsky PA, Mitra N, Vardhanabhuti S, Li M, Vaughn DJ, Letrero R et al. (2009) Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet 41, 811-815.
16. Kristiansen W, Haugen TB, Witczak O, Andersen JM, Fosså SD & Aschim EL. (2011) CYP1A1, CYP3A5 and CYP3A7 polymorphisms and testicular cancer susceptibility. Int J Androl 34, 77-83.
17. Kristiansen W, Andreassen KE, Karlsson R, Aschim EL, Bremnes RM, Dahl O et al. (2012) Gene variations in sex hormone pathways and the risk of testicular germ cell tumour: a case-parent triad study in a Norwegian-Swedish population. Hum Reprod 27, 1525-1535.
18. La Spada AR, Wilson EM, Lubahn DB, Harding AE & Fischbeck KH. (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77-79.
19. Lambrot R, Muczynski V, Lécureuil C, Angenard G, Coffigny H, Pairault C et al. (2009) Phthalates impair germ cell development in the human fetal testis in vitro without change in testosterone production. Environ Health Perspect 117, 32-37.
20. Li J, Coates RJ, Gwinn M & Khoury MJ. (2009) Steroid 5-{alpha}-reductase type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review. Am J Epidemiol 171, 1-13.
21. Lubahn DB, Tan JA, Quarmby VE, Sar M, Joseph DR, French FS & Wilson EM. (1989) Structural analysis of the human and rat androgen receptors and expression in male reproductive tract tissues. Ann N Y Acad Sci 564, 48-56.
22. Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN et al. (1997) A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res 57, 1020-1022.
23. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE & Reichardt JK. (1999) Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354, 975-978.
24. Malm G, Haugen TB, Henrichsen T, Bjorsvik C, Grotmol T, Saether T et al. (2004) Reproductive function during summer and winter in Norwegian men living north and south of the Arctic circle. J Clin Endocrinol Metab 89, 4397-4402.
25. Mongan NP, Hughes IA & Lim HN. (2002) Evidence that luteinising hormone receptor polymorphisms may contribute to male under masculinisation. Eur J Endocrinol 147, 103-107.
26. Nenonen H, Björk C, Skjaerpe P-A, Giwercman A, Rylander L, Svartberg J & Giwercman YL. (2010) CAG repeat number is not inversely associated with androgen receptor activity in vitro. Mol Hum Reprod 16, 153-157.
27. Ntais C, Polycarpou A & Ioannidis JP. (2003) SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 12, 618-624.
28. Piersma D, Verhoef-Post M, Look MP, Uitterlinden AG, Pols HA, Berns EM & Themmen AP. (2007) Polymorphic variations in Exon 10 of the luteinizing hormone receptor: functional consequences and associations with breast cancer. Mol Cell Endocrinol 276, 63-70.
29. Pleskacova J, Hersmus R, Oosterhuis JW, Setyawati BA, Faradz SM, Cools M et al. (2010) Tumor risk in disorders of sex development. Sex Dev 4, 259-269.
30. Rajpert-De Meyts E. (2006) Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. Hum Reprod Update 12, 303-323.
31. Rajpert-De Meyts E & Skakkebaek NE. (1993) The possible role of sex hormones in the development of testicular cancer. Eur Urol 23, 54-59; discussion 51-60.
32. Rajpert-De Meyts E, Leffers H, Daugaard G, Andersen CB, Petersen PM, Hinrichsen J, Pedersen LG & Skakkebaek NE. (2002) Analysis of the polymorphic CAG repeat length in the androgen receptor gene in patients with testicular germ cell cancer. Int J Cancer 102, 201-204.
33. Rapley EA, Turnbull C, Al Olama AA, Dermitzakis ET, Linger R, Huddart RA et al. (2009) A genome-wide association study of testicular germ cell tumor. Nat Genet 41, 807-810.
34. Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC & Ross RK. (1995) Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res 55, 3973-3975.
35. Richiardi L, Bellocco R, Adami H-O, Torrang A, Barlow L, Hakulinen T et al. (2004) Testicular cancer incidence in eight northern European countries: secular and recent trends. Cancer Epidemiol Biomarkers Prev 13, 2157-2166.
36. Sharpe RM. (2001) Hormones and testis development and the possible adverse effects of environmental chemicals. Toxicol Lett 120, 221-232.
37. Sharpe RM. (2003) The 'oestrogen hypothesis'- where do we stand now? Int J Androl 26, 2-15.
38. Sharpe R. (2006) Pathways of endocrine disruption during male sexual differentiation and masculinisation. Best Pract Res Clin Endocrinol Metab 20, 91-110.
39. Sharpe RM & Skakkebaek NE. (2008) Testicular dysgenesis syndrome: mechanistic insights and potential new downstream effects. Fertil Steril 89, e33-e38.
40. Simoni M, Tuttelmann F, Michel C, Bockenfeld Y, Nieschlag E & Gromoll J. (2008) Polymorphisms of the luteinizing hormone/chorionic gonadotropin receptor gene: association with maldescended testes and male infertility. Pharmacogenet Genomics 18, 193-200.
41. Skakkebaek NE, Rajpert-De Meyts E & Main KM. (2001) Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 16, 972-978.
42. Sonneveld DJ, Sleijfer DT, Schraffordt Koops H, Sijmons RH, van der Graaf WTA, Sluiter WJ & Hoekstra HJ. (1999) Familial testicular cancer in a single-centre population. Eur J Cancer 35, 1368-1373.
43. Themmen APN & Huhtaniemi IT. (2000) Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr Rev 21, 551-583.
44. Tsai MJ & O'Malley BW. (1994) Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63, 451-486.
45. Turnbull C, Rapley EA, Seal S, Pernet D, Renwick A, Hughes D et al. (2010) Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nat Genet 42, 604-607.
46. Västermark Å, Giwercman YL, Hagströmer O, De-Meyts ER, Eberhard J, Ståhl O et al. (2011) Polymorphic variation in the androgen receptor gene: association with risk of testicular germ cell cancer and metastatic disease. Eur J Cancer 47, 413-419.
47. Willemse PH, Sleijfer DT, Sluiter WJ, Schraffordt Koops H & Doorenbos H. (1983) Altered Leydig cell function in patients with testicular cancer: evidence for bilateral testicular defect. Acta Endocrinol (Copenh) 102, 616-624.
48. Wohlfahrt-Veje C, Main KM & Skakkebæk NE. (2009) Testicular dysgenesis syndrome; fetal origin of adult reproductive problems. Clin Endocrinol (Oxf) 71, 459-465.